Table 2 Summary of treatment efficacy assessed by the investigator

From: Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

Responses

All patients (n = 30)

CR, n (%)

1 (3.3)

PR, n (%)

23 (76.7)

SD, n (%)

4 (13.3)

PD, n (%)

1 (3.3)

NE, n (%)

1 (3.3)

ORR, n (%)

24 (80.0) (95% CI: 61.4–92.3)

DCR, n (%)

28 (93.3) (95% CI: 77.9–99.2)

Median DoR

11 months (95% CI: 7.8–15 months)

Median TTR

2.1 months (95% CI: 2.07-2.13months)

Median PFS

10.2 months (95% CI: 9.3–16.8 months)

Median OS

22.5 months (95% CI: 15.6 months–29.3 months)

1-year OS (%)

76.7 (95% CI: 62.9–93.4)

1-year PFS (%)

41.4 (95% CI: 26.8–63.8)

2-year OS (%)

49.8 (95% CI: 34.7–71.4)

  1. CR complete response, PR partial response, SD stable disease, PD progression disease, NE not evaluable, ORR objective response rate, DCR disease control rate, DoR duration of response, TTR time to response, PFS progression-free survival, OS overall survival, CI confidence interval
Back to article page